略歴
- 1985 年(昭和60 年) 大分医科大学卒業
- 1989 年(平成 元年) 大分医科大学大学院医学研究科博士課程修了
- 1989 年(平成 元年) 自治医科大学臨床薬理学助手
- 1991 年(平成 3 年) 米国ミネソタ大学医学部時間生物学教室
- 1995 年(平成 7 年) 北里大学医学部薬理学講師
- 2011 年(平成23 年) 北里大学医学部附属臨床研究センター 教授
- 2013 年(平成25 年) 北里大学病院臨床試験センター センター長
- 2023 年(令和5年) 北里大学名誉教授
主な研究内容
臨床薬理学、高血圧症、心電図病学、時間生物学
臨床研究方法論
発表論文
Kumagai,Y., Shiga,T., Sunaga,K., Cornelissen,G., Ebihara,A., and Halberg,F.: Usefulness of circadian amplitude of blood pressure in prediciting hypertensive cardiac involvement. Chronobiologia 19:43-58, 1992.
Kumagai,Y., Shiga,T., Sunaga,K., Fukushima,C., Cornelissen,G., Ebihara,A. and Halberg,F.: Repeated alcohol intake changes circadian rhythm of ambulatory blood pressure. Chronobiologia 20:77-85, 1993.
Kumagai,Y. : Strategies against high blood pressure in the early morning. Clinical and Experimental Hypertension, 26(2), pp107-118, 2004.
Kumagai Y, Fujita T, Oｚaki M, Sahashi K, Ohkura M, Ohtsu T, Arai Y, Sonehara Y, Nichol JL.：Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: A randomized, placebo-controlled study. J Clin Pharmacol, 47(12):1489-97, 2007.
Kumagai,Y., Hasunuma,T., Padhi,D.: A randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab administered subcutaneously to postmenopausal Japanese women.
Kumagai Y, Murakawa Y, Hasunuma T, Aso M, Yuji W, Sakurai T, Noto M, OeT, Kaneko A: Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults, Int J Clin Pharmacol Ther. 53(10):866-74, 2015 Oct.
Kumagai Y, Hasunuma T, Sakai S, Ochiai H, Samukawa Y: Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects, PLoS One, 10(10):e0139873, 2015 Oct.
Kumagai,Y., Amano,H. et al.; Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: A randomized controlled trial.,Br J Clin Pharmacol,84(10)2393-2404,2018 Oct.
Kumagai Y, Ose A, Tanaka K, Sugimoto T.: Safety Profiles, Pharmacokinetics, and Changes in Bone Turnover Markers After Twice-Weekly Subcutaneous Administration of Teriparatide in Healthy Japanese Postmenopausal Women: A Single-Blind Randomized Study., Clin Pharmacol Drug Dev., 9(1)87-96, 2020. Kumagai,Y., Sakaki,M., et al.: Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment, Clinical and Experimental Nephrology, 24 (Suppl1):S25–S35,2020 Mar. Kumagai,Y., Fujita,T. et al.: A Drug-Drug Interaction Study to Evaluate the Effect of TAS-303 on CYP3A Activity in the Small Intestine and Liver, The Journal of Clinical Pharmacology, 2020, 60(6) 702–710,2020 Jun.
Oda,Y., Kumagai,Y. et al; Immunogenicity and safety of a booster dose of a self―amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet Infection 2023 https://doi.org/10.1016/S1473-3099(23)00650-3